8-K: Crinetics Pharmaceuticals Implements Excess Deferral Plan for Executives and Directors

Crinetics Pharmaceuticals has adopted an Excess Deferral Plan, effective April 1, 2024, allowing eligible employees and directors to defer compensation.

Summary

• Crinetics Pharmaceuticals has established an Excess Deferral Plan, effective April 1, 2024.
• This plan is a non-qualified deferred compensation plan designed to comply with Section 409A of the Internal Revenue Code.
• Participation is limited to select management, highly compensated employees, named executive officers, and non-employee directors.
• Participants can defer portions of their annual compensation, including salaries, director fees, bonuses, and restricted stock units.
• Deferral elections must be made in advance according to the plan's rules.
• The company may also make matching or discretionary contributions to participant accounts.
• Account balances will be treated as if invested in available investment options, with adjustments for hypothetical earnings, expenses, gains, or losses.
• Participants are fully vested in their elective deferrals and matching contributions.
• Vesting of discretionary contributions will follow a schedule outlined in the plan.
• Non-vested amounts are forfeited upon separation from the company.
• Payments of vested amounts will generally occur after separation or at an earlier elected in-service date.

Sentiment

Score: 7

Explanation: The announcement is a standard corporate action, indicating a positive step in aligning executive interests with the company's long-term goals. It is not a major event but is a positive development.

Positives

• The Excess Deferral Plan provides a tax-advantaged way for executives and directors to save for the future.
• The plan allows for flexibility in deferral elections and investment options.
• The company's matching contributions can enhance the value of the plan for participants.
• The plan is designed to comply with Section 409A of the Internal Revenue Code, ensuring regulatory compliance.

Negatives

• Non-vested discretionary contributions are forfeited upon separation from the company.
• The plan is unfunded, meaning that participants are subject to the credit risk of the company.

Risks

• The plan is unfunded, meaning that participants are subject to the credit risk of the company.
• Changes in tax laws could impact the benefits of the plan.
• The plan's investment options may not perform as expected, impacting the value of deferred compensation.

Future Outlook

The plan will be administered according to its terms, with payments generally made following a participant's separation from service or at an earlier elected in-service payment date.

Management Comments

• The Board of Directors of Crinetics Pharmaceuticals, Inc. approved the adoption of the Crinetics Pharmaceuticals, Inc. Excess Deferral Plan.

Industry Context

Deferred compensation plans are a common practice among publicly traded companies to attract and retain key talent, aligning their interests with the long-term success of the company.

Comparison to Industry Standards

• Many publicly traded companies offer deferred compensation plans to their executives and directors.
• These plans are often designed to comply with Section 409A of the Internal Revenue Code, similar to the Crinetics plan.
• The specific terms and conditions of these plans can vary, but the general structure of deferring compensation and providing investment options is common.
• Companies like Amgen, Biogen, and Gilead Sciences also have similar deferred compensation plans for their executives.

Stakeholder Impact

• Shareholders may view the plan positively as it aligns executive interests with the long-term success of the company.
• Eligible employees and directors will benefit from the tax-advantaged savings opportunities.
• The plan may help attract and retain key talent.

Next Steps

• The company will administer the plan according to its terms.
• Eligible employees and directors will make deferral elections in accordance with the plan's rules.

Key Dates

Keywords

Deferred Compensation, Executive Compensation, Employee Benefits, Section 409A, Crinetics Pharmaceuticals, Stock Options, Directors Fees